RxMarketSCIENCE is an Industry, Policy and Strategy Research, Analysis, Evaluation and Education firm specialized in the study of global business eco-system of prescription drugs. We are the unbiased experts of the prescription drug commerce eco-system. Our mission at RxMarketSCIENCE is to make our industry knowledge available for prescription drug industry practitioners, firms, investors and key stakeholders through our engagements and research services.
STRATEGIC INSIGHTS TO NEXT LEVEL
We believe that strategic decision-making requires the ability to research the problem and its potential solutions within its context. However, this requires deep and comprehensive industry knowledge first. RxMarketSCIENCE helps elevate your strategic insights and decision-making ability to the next level. Whether it is an Industry Development, Policy Change or Strategic Change, it helps to understand the deeper level underpinnings of the situation before you make any changes.
Derived from our consulting experience, industry expertise, ongoing studies and research, the insights we provide have been very valuable for our clients and customers. The minds behind RxMarketSCIENCE have been helping the following segments for more than a decade:
PRIVATE EQUITY FIRMS
Brings industry expertise on your side. Helps make decisions based on deep industry knowledge and context.
MANAGEMENT CONSULTING FIRMS
Enhances the consulting teams’ capability and knowledge on-demand. Decreases learning curve for new consultants.
CORPORATE STRATEGY GROUPS
Brings outside perspectives and market experiments support and practice-oriented research skills.
Accelerate the industry landscape knowledge and help bring new solutions to market while minimizing market iteration.
Helps de-code industry developments, strategy maneuvers by industry firms and policy changes. Decreases the learning cycle for new associates.
ON THE DOMAINS THAT DRIVE THE BUSINESS OF MEDICINES
Through our experience and studies , we found 4 main domains every stakeholder must deeply understand as they make strategic decisions. RxMarketSCIENCE helps clients navigate through these domains.
How does the government policy and regulations impact the industry dynamics
How does the industry's evolutionary dynamics affect competitive strategy and affect the positioning of companies
What is the true merit of competitive strategy employed or communicated by the industry players?
How new technologies and innovative services can affect the industry eco-system
THE EXPERTISE ON SYSTEMIC AND INTER-SEGMENT ISSUES
We never stop learning. We believe that systemic industry expertise is a must for a good strategist in the prescription drug industry eco-system. We also know it is hard for an expert in one firm to learn other segments within the industry. Hence we focus on broader and deeper expertise building in the end-to-end drug commerce system in order to help our clients. Our clients rely on our advice, positions and opinions on the major decisions they make.
GLOBAL & DOMESTIC DRUG COMMERCE SYSTEM & ITS ECONOMICS
Our focus is the global drug commerce system in between the drug/ingredients manufacturer and the patient. We study the flow of money, product and information (and their economics) between the patients and drug/ingredient manufacturers.
DRUG BENEFIT, ACCESS AND PAYMENTS SEGMENTS
Drug benefit, access and payment decisions indirectly or directly control many other aspects of the US drug commerce system. No major decisions on this industry can be made without clearly understanding these three aspects of the industry.
Rx TECHNOLOGIES, DATA & INFORMATICS SEGMENTS
Technology, data and informatics makes everything happen in this industry. With the new developments in data science and artificial intelligence, the new game business models of this segment is set to transform the way many things happen in the drug industry.
PHARMACEUTICAL CARE & OUTCOMES MANAGEMENT SEGMENTS
The topic of business of medicines is not complete without the considering the business of drug outcomes. Ultimately, from a societal perspective, the goal the business of medicines is to improve outcomes